|
Match
|
Document |
Document Title |
|
|
US20110251121 |
USE OF CYSTEINE-RICH WHEY DERIVED PROTEIN IN PATIENTS RECEIVING CHEMOTHERAPY AND/OR RADIOTHERAPY TO IMPROVE PATIENT SURVIVAL
A cysteine-rich undenatured whey-derived protein formulation did not interfere with the tumor-cytotoxic effects of chemotherapy and radiation therapy and did not have a negative effect on the... |
|
|
US20120021971 |
Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof
The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic... |
|
|
US20140213510 |
USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME
The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of... |
|
|
US20110028389 |
USE OF INFANT FORMULA WITH REDUCED PROTEIN CONTENT
A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a... |
|
|
US20150099695 |
C1q/TNF-RELATED PROTEIN-9 (CTRP9) AND USE IN PREVENTION AND TREATMENT OF METABOLIC DISORDERS
Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an... |
|
|
US20120129766 |
METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods... |
|
|
US20110256063 |
MEX3C REGULATION AND TARGET TO CONTROL OBESITY AND DIABETES
MEX3C deficiency impairs the development of white and brown adipose tissue. Hence the present invention provides, among other things, a method of screening a candidate compound for activity in... |
|
|
US20110256130 |
METHODS OF TREATING INFLAMMATORY DISORDERS
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of... |
|
|
US20120219616 |
LIPOSOMAL REDUCED GLUTATHIONE AND l-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS
The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals... |
|
|
US20110144006 |
PROTEIN COMPOSITION
The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L.... |
|
|
US20110263490 |
Diagnostic Methods and Combination Therapies Involving MC4R
Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of... |
|
|
US20140155316 |
FIBROBLAST GROWTH FACTOR 1 PROTEIN FRAGMENTS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20150080294 |
METHODS FOR PROMOTING LIPOLYSIS AND OXIDATION IN LIVER AND ADIPOSE TISSUE USING CATESTATIN
The invention provides methods for treating obesity in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with obesity so as to... |
|
|
US20110091543 |
ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS
Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed.... |
|
|
US20130216537 |
Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss
Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided. |
|
|
US20120282184 |
TREATMENT OF OBESITY
A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to... |
|
|
US20100184640 |
DOG DIABETES
A method a method for diagnosing susceptibility to diabetes in a non-human animal, the method comprising: a) identifying whether or not a polymorphism as defined in Table 4 or a polymorphism which... |
|
|
US20150065419 |
METHODS FOR TREATING METABOLIC DISORDERS USING FGF
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. |
|
|
US20140171361 |
METHODS FOR TREATING METABOLIC DISORDERS USING FGF
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. |
|
|
US20130116171 |
METHODS FOR TREATING METABOLIC DISORDERS USING FGF
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. |
|
|
US20130202681 |
LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE FOR MANAGEMENT OF CANCER AND DISRUPTION OF CANCER ENERGY CYCLES
A method of treatment of cancer with a formulation of liposomally encapsulated glutathione, that is preferably used orally, increases the level of glutathione in tissues in order to prevent and... |
|
|
US20110002994 |
METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to... |
|
|
US20110293725 |
CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME
Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a... |
|
|
US20140011737 |
COMPOSITIONS AND METHODS FOR REGULATING METABOLISM
The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein. |
|
|
US20150023960 |
Compositions and Methods of Use for Treating Metabolic Disorders
Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. |
|
|
US20140213511 |
COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS
Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. |
|
|
US20110212887 |
METHODS OF TREATING OBESITY USING ENTEROSTATIN
The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount... |
|
|
US20100316644 |
TRUNCATED ACTRIIB-FC FUSION PROTEINS
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or... |
|
|
US20140073562 |
NASAL DELIVERY
A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a... |
|
|
US20120207680 |
Methods of Identifying Candidate Compounds of the Human G Protein-Coupled Receptor, GPR50, as Modulators of Body Mass or Adiposity
The present invention relates to methods of using a G protein-coupled receptor (GPCR) to screen one or more candidate compounds as a modulator of body mass or of adiposity or of percentage body... |
|
|
US20110003013 |
METHOD OF INCREASING METABOLISM
The present invention provides a method for increasing metabolism and/or energy expenditure in a subject, e.g., to treat or prevent obesity and/or a related condition and/or to reduce adiposity,... |
|
|
US20150202259 |
TARGETED OESOPHAGEAL ADMINISTRATION OF ZN-ALPHA2-GLYCOPROTEINS (ZAG), METHODS AND FORMULATIONS THEREOF
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to... |
|
|
US20130065821 |
COMPOSITION FOR PREVENTING AND IMPROVING METABOLIC SYNDROME
A method for improving blood HDL/LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, and/or reducing body weight, that includes ingesting a composition containing... |
|
|
US20120178672 |
Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
A nutritional composition and method of use that improves the net balance in skeletal muscle by targeting both the synthetic and breakdown processes. The disclosed composition provides for... |
|
|
US20140107019 |
ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which... |
|
|
US20130202646 |
COMPOSITIONS AND METHODS FOR MODULATING AUTOPHAGY
In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1... |
|
|
US20120093883 |
METHOD OF TREATING AND PREVENTING NEURO-OLFACTORY TRIGGERED OR AGGRAVATED ILLNESSES OR RELATED CONDITIONS
A method for treating at least one of neuro-olfactory triggered illnesses, and related conditions within a subject is provided. The method includes the steps of: a) providing a composition that... |
|
|
US20100311649 |
SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R).... |
|
|
US20110177097 |
METHODS FOR MODULATING EXPRESSION OF CREB
Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or... |
|
|
US20110123521 |
METHODS FOR MODULATING EXPRESSION OF RBP4
Methods are provided for modulating RBP4 by administering a RBP4-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or... |
|
|
US20110130783 |
TREATMENT OF OBESITY AND RELATED DISORDERS
This disclosure provides a method of treating obesity and related disorders through the administration of a composition comprising a neurotoxin and a mucosal permeabilizing agent. Methods for... |
|
|
US20130210713 |
COLLAGEN POWDER
The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the... |
|
|
US20140057837 |
METHODS AND COMPOSITIONS FOR THE "BROWNING" OF WHITE FAT
Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become... |
|
|
US20130324462 |
Method of Reducing The Effects of Chemotherapy Using Flagellin Related Polypeptides
The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described. |
|
|
US20110243923 |
ORGANIC COMPOUNDS
The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or... |
|
|
US20120004163 |
NUTRITIONAL COMPOSITION FOR INFANTS
A nutritional composition for infants comprises a protein source, a lipid source and a carbohydrate source wherein the lipid source includes at least 16 wt % linoleic acid and at least 2 wt %... |
|
|
US20130231277 |
CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR BETA-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”)... |
|
|
US20110245178 |
Exendin Fusion Proteins
The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and... |
|
|
US20140213512 |
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia,... |
|
|
US20110200580 |
METHODS OF TREATMENT AND PREVENTION OF DIET-INDUCED OBESITY AND SEQUELAE THEREOF
Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at... |